

1645
RECEIVED
NOV 13 2002
TECH CENTER 1600/1600

TRANSMITTAL LETTER			Case No. 9793/93
Serial No. 10/057,762	Filing Date January 25, 2002	Examiner	Group Art Unit 1645
Inventor(s) Min Li, et al.			
Title of Invention Water-Soluble Derivatives Of Lipophilic Drugs			

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is Transmittal Letter (2), Information Disclosure Statement (2), Form PTO-1449, Copies of Cited References A1-A17, Postcard Receipt.

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- ☐ Petition for a _____ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity		or	Other Than Small Entity	
Rate	Add'l Fee		Rate	Add'l Fee
x \$9 =			x \$18 =	
x 42 =			x \$84 =	
+ \$140 =			+ \$280 =	
Total add'l fee	\$		Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$_____. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$_____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Jonathan P. Tayldr
Registration No. 48,338
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on November 7, 2002.

Date: Nov. 7, 2002

Signature:

rev. Dec.-00

Copied from 09848733 on 21-04-2004



RECEIVED
NOV 18 2002
TECH CENTER 160012900

TRANSMITTAL LETTER			Case No. 9793/93
Serial No. 10/057,762	Filing Date January 25, 2002	Examiner	Group Art Unit 1645
Inventor(s) Min Li, et al.			
Title of Invention Water-Soluble Derivatives Of Lipophilic Drugs			

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is Transmittal Letter (2), Information Disclosure Statement (2), Form PTO-1449, Copies of Cited References A1-A17, Postcard Receipt.

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- ☐ Petition for a _____ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:


	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity	
Rate	Add'l Fee
x \$9 =	
x 42 =	
+ \$140 =	
Total add'l fee	\$

Other Than Small Entity	
Rate	Add'l Fee
x \$18 =	
x \$84 =	
+ \$280 =	
Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$_____. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$_____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


Jonathan P. Taylor
Registration No. 48,338
Agent for Applicant

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, O.C. 20231, on November 7, 2002.

Date: Nov. 7, 2002

Signature: 

rev. Dec.-00

Copied from 09848733 on 21-04-2004



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on

November 7, 2002

Date of Deposit

Jonathan P. Taylor

Name of Applicant, Assignee or
Registered Representative


Signature

November 7, 2002

Date of Signature

RECEIVED
NOV 13 2002
TECH CENTER 1600/2900

Our Case No.: 9793/93

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Min Li, et al.

Serial No.: 10/057,762

Filing Date: January 25, 2002

For: Water-Soluble Derivatives Of
Lipophilic Drugs

Examiner:

Group Art Unit No.: 1645

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

REFERENCE DESIGNATION			U.S. PATENT DOCUMENTS		
	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
A1	3,567,710	03-02-1971	Fryer, et al.	260/239.3	06-03-1968
A2	4,043,989	08-23-1977	Schneider, et al.	260/112	09-11-1975
A3	4,046,636	09-06-1977	Ullman et al.	195/63	05-24-1976
A4	4,083,948	04-11-1978	Davis et al.	424/1	04-04-1977
A5	4,243,654	01-06-1981	Schneider et al.	424/12	09-11-1978
A6	4,777,169	10-11-1988	Earley et al.	514/221	11-06-1987
A7	5,144,030	09-01-1992	Wang et al.	546/89	06-12-1989
A8	5,237,057	08-17-1993	Buechler et al.	536/119	04-06-1992
A9	5,770,458	06-23-1998	Klimov et al.	436/518	06-17-1997

FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO
A10	0 246 797 B1	11-25-1987	EPO		


OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
A11	Andrew Streitwieser, Jr., et al., University of California, Berkeley, <i>Introduction To Organic Chemistry</i> , Third Edition (1985), pp. 698-707, 766-769, 776-780.
A12	Jerry March, Professor of Chemistry, Adelphi University, <i>Advanced Organic Chemistry – Reactions, Mechanisms, And Structure</i> , Fourth Edition (1992), pp. 410-411, 499-500, 1199-1200.
A13	W.R. Dixon, et al, <i>Radioimmunoassay Of The Anticonvulsant Agent Clonazepam</i> , JOURNAL OF PHARMACEUTICAL SCIENCES, Vol. 66, No. 2, February 1977, pp. 235-237.
A14	Bernard Peskar, et al., <i>Quantitative Determination of Diazepam In Blood By Radioimmunoassay</i> , THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol. 186, No. 1 (1973), pp. 167-172.
A15	R. Sherman-Gold, et al., Department of Neurobiology and Department of Chemical Immunology, The Weizmann Institute of Science, <i>Production of a High Affinity Antiserum to Benzodiazepines</i> , JOURNAL OF IMMUNOASSAY, 4(2), 135-146 (1983).
A16	G. Galfré, et al., <i>Preparation of Monoclonal Antibodies: Strategies and Procedures</i> , METHODS IN ENZYMOLOGY, VOLUME 73, IMMUNOCHEMICAL TECHNIQUES, PART B, John J. Langone, et al, Editors, pp. 3-46 (1981).
A17	Frank L. Adler, et al., <i>Detection of Morphine by Hemagglutination-Inhibition</i> , THE JOURNAL OF IMMUNOLOGY (1971), pp. 1684-1685.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Jonathan P. Taylor
Registration No. 48,338
Agent for Applicants

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200